SecSonar.com

Precigen, Inc. (PGEN)

Precigen, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Precigen, Inc. (PGEN) is a Biotechnology company based in US with a market capitalization of $1.3B. Revenue grew 146.7% year-over-year and free cash flow was negative at -$89.8M. This page tracks PGEN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 143 employees · IPO Aug 8, 2013

Valuation

Valuation & price

$4.42 · as of May 17, 2026 · -25.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

63.86

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$5.86$3.72$1.57Jul 25Dec 25Jul 26Jul 7, 25$1.59Jul 9, 25$1.90Jul 11, 25$1.83Jul 15, 25$1.85Jul 17, 25$1.82Jul 21, 25$1.83Jul 23, 25$1.66Jul 25, 25$1.57Jul 29, 25$1.57Jul 31, 25$1.71Aug 4, 25$1.76Aug 6, 25$1.83Aug 11, 25$1.74Aug 13, 25$1.91Aug 15, 25$2.94Aug 19, 25$3.22Aug 21, 25$3.64Aug 25, 25$3.98Aug 27, 25$4.59Aug 29, 25$4.51Sep 3, 25$4.75Sep 5, 25$4.36Sep 9, 25$4.13Sep 11, 25$4.14Sep 16, 25$3.89Sep 18, 25$3.80Sep 22, 25$3.85Sep 24, 25$3.86Sep 26, 25$3.51Sep 30, 25$3.29Oct 2, 25$3.33Oct 6, 25$3.14Oct 8, 25$3.22Oct 10, 25$3.12Oct 14, 25$3.20Oct 16, 25$3.49Oct 21, 25$4.08Oct 23, 25$4.25Oct 27, 25$4.30Oct 29, 25$4.01Oct 31, 25$4.14Nov 4, 25$3.88Nov 6, 25$3.92Nov 10, 25$4.00Nov 12, 25$4.02Nov 14, 25$4.85Nov 18, 25$4.85Nov 20, 25$3.90Nov 25, 25$3.67Nov 28, 25$3.83Dec 2, 25$3.48Dec 4, 25$3.75Dec 8, 25$3.69Dec 10, 25$3.51Dec 12, 25$3.69Dec 16, 25$3.87Dec 18, 25$4.17Dec 22, 25$4.38Dec 24, 25$4.19Dec 29, 25$4.45Jan 2, 26$4.28Jan 6, 26$4.55Jan 8, 26$4.61Jan 12, 26$4.14Jan 14, 26$4.41Jan 16, 26$4.41Jan 21, 26$4.46Jan 23, 26$4.76Jan 27, 26$4.73Jan 29, 26$4.53Feb 2, 26$4.83Feb 4, 26$4.56Feb 9, 26$4.56Feb 11, 26$4.91Feb 13, 26$4.93Feb 18, 26$4.88Feb 20, 26$4.38Feb 24, 26$3.98Feb 26, 26$3.81Mar 2, 26$3.62Mar 4, 26$3.55Mar 6, 26$3.32Mar 10, 26$3.51Mar 12, 26$3.28Mar 17, 26$3.54Mar 19, 26$3.32Mar 23, 26$3.24Mar 25, 26$3.10Mar 27, 26$3.67Mar 31, 26$3.87Apr 2, 26$3.94Apr 7, 26$4.12Apr 9, 26$4.27Apr 13, 26$4.17Apr 15, 26$3.90Apr 17, 26$3.98Apr 22, 26$3.96Apr 24, 26$4.13Apr 28, 26$4.02Apr 30, 26$4.16May 4, 26$4.14May 6, 26$4.40May 8, 26$4.21May 12, 26$4.08May 14, 26$4.60May 18, 26$4.07May 20, 26$4.27May 22, 26$4.24May 28, 26$4.51Jun 1, 26$4.12Jun 3, 26$3.81Jun 5, 26$3.58Jun 9, 26$3.71Jun 11, 26$4.53Jun 15, 26$4.80Jun 17, 26$4.73Jun 22, 26$5.38Jun 24, 26$5.40Jun 26, 26$5.86Jul 2, 26$5.64
$1.5252-week range$5.92
Loading valuation history…

Fundamentals

Key fundamentals

$1.3B

Market cap

146.7%

Revenue growth (YoY)

37.0%

Gross margin

-$89.8M

Free cash flow (USD)

-$92.7M

Net debt

Net cash position

13.8%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$190.9MFY 2017$231.0MFY 2018$160.6MFY 2019$32.0MFY 2020$32.0MFY 2021$14.3MFY 2022$26.9MFY 2023$6.2MFY 2024$3.9MFY 2025$9.7M
$190.9M$9.7M

Free cash flow by year

2016 → 2025

FY 2016$-87.6MFY 2017$-150.8MFY 2018$-165.8MFY 2019$-84.5MFY 2020$-84.5MFY 2021$-63.0MFY 2022$-70.0MFY 2023$-68.5MFY 2024$-76.8MFY 2025$-89.8M
-$87.6M-$89.8M

Gross margin by year

2021 → 2025

FY 2021-276.2%FY 202276.4%FY 20231.7%FY 2024-8.7%FY 202537.0%
-276.2%37.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $251K · 10b5-1 PlanShah Rutul R · Chief Operating Officer · $251.1KJul 1, 2026Filing
  • Insider sellInsider Sell $1.1M · 10b5-1 PlanThomasian Harry Jr. · Chief Financial Officer · $1.1MJul 1, 2026Filing
  • Insider sellInsider Sell $2.0M · 10b5-1 PlanSabzevari Helen · President and CEO · $2MJul 1, 2026Filing
  • 8-K eventStockholder Meeting ResultsJun 24, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing

Questions

Frequently asked questions

What is Precigen, Inc.'s market cap?

Precigen, Inc. (PGEN) has a market capitalization of $1.3B.

What is PGEN's P/E ratio?

A meaningful P/E ratio is not available for PGEN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is PGEN's price-to-book (P/B) ratio?

PGEN trades at 63.86 times book value per share.

Are insiders buying PGEN stock?

SEC Form 4 filings show no open-market insider buys at Precigen, Inc. in the last 90 days (3 sells).

Same arena

Related companies in Biotechnology

MRVI

Maravai LifeSciences Holdings, Inc.

$1.3B

SEPN

Septerna, Inc.

$1.4B

CAPR

Capricor Therapeutics, Inc.

$1.4B

URGN

UroGen Pharma Ltd.

$1.4B

WVE

Wave Life Sciences Ltd.

$1.3B

GLUE

Monte Rosa Therapeutics, Inc.

$1.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.